Non-small Cell Lung Cancer Clinical Trial
Official title:
Vedio-assisted Thoracoscopic Lobectomy vs Open Lobectomy for Patients With Surgically Resectable Pathologic N2 NSCLC
NCT number | NCT03613467 |
Other study ID # | W-TONG06 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | July 4, 2018 |
Est. completion date | July 6, 2018 |
Verified date | August 2018 |
Source | Tang-Du Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The study was designed to compare the safety and effectiveness of vedio-assisted thoracoscopic lobectomy with open lobectomy for patients with surgically resectable pathologic N2 non-small cell lung cancer
Status | Completed |
Enrollment | 2145 |
Est. completion date | July 6, 2018 |
Est. primary completion date | July 4, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with age > 18 years old; - Patients with pathologically diagnosed non-small cell lung cancer; - Patients underwent lobectomy by either VATS or thoracotomy between 2014 and 2017; - Patients who received lymphadenectomy for all accessible lymph nodes; - Patients with N2 lymph nodes (+) after surgeries; Exclusion Criteria: - Patients with second primary tumors or multiple primary tumors; - Patients who received chest surgeries before hospitalization; - Patients with superior pulmonary sulcus tumor |
Country | Name | City | State |
---|---|---|---|
China | China PLA General Hospital | Beijing | Beijing |
China | China-Japan Friendship Hospital | Beijing | Beijing |
China | Huaxi Hospital Affiliated to Sichuan University | Chengdu | Sichuan |
China | First Hospital Affiliated to Zhejiang University | Hangzhou | Zhejiang |
China | Jiangsu cancer hospital | Nanjing | Jiangsu |
China | Shanghai Chest Hospital | Shanghai | Shanghai |
China | Tianjin Chest Hospital | Tianjin | Tianjin |
China | Tongji Hospital Affiliated to Huazhong Technology Hospital | Wuhan | Hubei |
China | Xi'an Tangdu Hospital | Xi'an | Shaanxi |
China | Henan Cancer Hospital | Zhengzhou | Henan |
Lead Sponsor | Collaborator |
---|---|
Tang-Du Hospital | LinkDoc Technology (Beijing) Co. Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Overall survivals in the subgroups stratified by T staging | Overall survivals in the subgroups stratified by T staging | 2014-2018 | |
Other | Overall survivals in the subgroups stratified by neoadjuvant therapy | Overall survivals in the subgroups stratified by neoadjuvant therapy | 2014-2018 | |
Other | Overall survivals in the subgroups stratified by number of lymph node station involved | Overall survivals in the subgroups stratified by number of lymph node station involved | 2014-2018 | |
Other | Impact factors for overall survival | Impact factors for overall survival | 2014-2018 | |
Other | Impact factors for postoperative mortality within 30/90 days | Impact factors for postoperative mortality within 30/90 days | 2014-2017 | |
Other | Propensity score matching analysis of overall survival | Propensity score matching analysis of overall survival | 2014-2018 | |
Other | Propensity score matching analysis of perioperative outcomes | Propensity score matching analysis of perioperative outcomes | 2014-2018 | |
Other | Propensity score matching analysis of impact factors for overall survival | Propensity score matching analysis of impact factors for overall survival | 2014-2018 | |
Other | Propensity score matching analysis of impact factors for postoperative mortality within 30/90 days | Propensity score matching analysis of impact factors for postoperative mortality within 30/90 days | 2014-2018 | |
Primary | Overall survival | Overall survival | 2014-2018 | |
Secondary | Duration of hospital stay [Perioperative outcomes] | Duration of hospital stay [Perioperative outcomes] | 2014-2017 | |
Secondary | Postoperative 30 and 90 days [Perioperative outcomes] | Postoperative 30 and 90 days [Perioperative outcomes] | 2014-2017 | |
Secondary | Drainage time [Perioperative outcomes] | Drainage time [Perioperative outcomes] | 2014-2017 | |
Secondary | Intraoperative blood loss [Perioperative outcomes] | Intraoperative blood loss [Perioperative outcomes] | 2014-2017 | |
Secondary | Postoperative complications [Perioperative outcomes] | Postoperative complications [Perioperative outcomes] | 2014-2017 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |